In the ALEX trial, alectinib had a significant PFS advantage over crizotinib (median PFS 34.8 vs. 10.9 months, HR 0.43) in untreated ALK-positive patients with advanced NSCLC with similar safety outcomes [13]. This evidence concerns the gene ALK and non-small cell lung carcinoma.